High Responses, Safety Are Reviewed for Liso-Cel in FL
Treatment with liso-cel had a manageable safety profile with no new safety signals in patients with relapsed/ refractory follicular lymphoma.
COMBO300 Shows Benefit Without Severe Toxicity in Advanced BRAF V600+ Melanoma
According to investigators of the phase 3 COLUMBUS study, BRAF/MEK inhibitor combinations are better with more BRAF inhibition.
Phase 1/2 Study Investigates Fadraciclib for Solid Tumors and Lymphoma
Fadraciclib, a highly selective inhibitor of CDK2 and CDK9, is being investigated in clinical trials for patients with solid tumors and hematologic malignancies.
Olaparib With High-Dose Chemo and ASCT Shows Potential in R/R Lymphomas
In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.
Ziftomenib Induces Clinical Activity in NPM1-Mutated R/R AML
Ziftomenib showed safety and efficacy in heavily pretreated patients with comutations and NPM1-mutated, relapsed/refractory acute myeloid leukemia.
Belzutifan Improves Key Outcomes of LITESPARK-005 in Adults With Advanced RCC
According to Eric Jonasch, MD, promising findings from LITESPARK-005 may help with a goal of getting belzutifan FDA approval for patients with refractory renal cell carcinoma.
EV-103 Study Highlights Promise of Enfortumab Vedotin and Pembro in mUC
In an interview, Shilpa Gupta, MD, discussed findings from cohort A of Study EV-103 in patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma.
Trials of Rintatolimod Across Solid Tumor Types Continue to Advance
A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.
Amivantamab Plus Lazertinib May Be a Future Treatment Option for NSCLC
In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.
Emerging Therapies Are Explored in Low- and High-Risk MDS
For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.
Tucatinib Plus T-DM1 Lowers Risk of Progression or Death in HER2+ mBC
Data from HER2CLIMB-02 will be presented at an upcoming medical meeting and the results will be shared with the FDA.
Trials Seek to Assess New Treatments for Lower-Risk MDS
Guillermo Garcia-Manero, MD, discussed 2 studies evaluating therapies for patients with lower-risk myelodysplastic syndrome.
8-Year OS Similar Between Neratinib and Placebo in HER2+ Breast Cancer
In an 8-year follow up analysis of patients on the ExteNET trial, researchers saw that overall survival was not significantly different to rates on placebo.
Garje Assesses Sarcomatoid vs Classic Urothelial Carcinoma
Rohan Garje, MD, explains some of the differences between the sarcomatoid and classic carcinoma of the bladder.
Validated Biomarkers in Renal Cell Carcinoma: The Search Continues
Several immunotherapies are now approved for the management of metastatic RCC. However, immunotherapy-based combination regimens are associated with high rates of treatment-related toxicities and do not yield objective responses in a significant proportion of patients.
Lessons from KEYNOTE-921 in Metastatic Castration Resistant Prostate Cancer
Daniel P. Petrylak, MD, highlights data from the phase 3 KEYNOTE-921 of pembrolizumab in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer.
Pegsitacianine Informs Surgery in Peritoneal Carcinomatosis
Currently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.
FDA Approves FoundationOne CDx to Identify Akeega Candidates with BRCA+ mCRPC
Ivosidenib Granted Priority Review by FDA for IDH1+ R/R Myelodysplastic Syndromes
The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.
BMI May Positively Impact the Pharmacodynamics of Palbociclib in Patients With eBC
According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.
FDA Approves HEPZATO KIT for Adults Metastatic With Uveal Melanoma
The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.
FDA Allows iMMagine-1 Study to Continue for Patients With RRMM
Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.
Immune Checkpoint Inhibitors Further Refine Hodgkin Lymphoma Regimens
During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.
LINKER-MM1 Supports Development of Linvoseltamab in Multiple Myeloma
In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.
FDA Greenlights Erlanatamab for Relapsed or Refractory Multiple Myeloma
Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.
Addressing Breast Cancer Overtreatment Concerns
An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.
Zanidatamab Shows Potential to Enter the Armamentarium for HER2+ BTC
Based on the largest clinical trial of patients with HER2-amplified biliary tract cancer, a novel anti-HER bispecific antibody may be the next option.
ROAR Study Update Solidifies Benefit of Dabrafenib/Trametinib in BRAF V600E+ ATC
Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.
Letrozole/Abemaciclib Generates Activity in ER+ Endometrial Cancer
Patients with hormone receptor-positive endometrial cancer had an objective response rate of 30%, including 8 confirmed responses, when treated with letrozole with abemaciclib.
FDA Approves Niraparib Plus Abiraterone Acetate and Prednisone for BRCA+ mCRPC
Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.
2 Clarke Drive Cranbury, NJ 08512